New Research - 2026
The UK POM
Digital Benchmark
We benchmarked the publicly visible product information of 100 UK POM marketing authorisation holders. Here is what we found — and what it means for mid-tier and specialist pharma.
How easy is it to find trusted product information for UK prescription medicines?
We reviewed the publicly visible digital product-information estates of 100 UK POM marketing authorisation holders and scored them against a consistent maturity framework.
The benchmark compares 91 mid-tier and specialist MAHs with a reference cohort of 9 Big Pharma companies, showing where the market is strong, where digital estates are fragmented, and where practical improvement opportunities exist.
For patients, HCPs and other stakeholders, finding the right information depends on more than whether a medicine is listed online. It depends on how clearly each company structures, signposts and governs its product-information estate.
What is a digital product-information estate?
A mature estate may be simple. What matters is whether it is clear, findable, audience-appropriate, consistent and maintainable over time.
Each estate was assessed on how well it is structured, audience-routed and governed by looking at whether:
Product-level information was available through company-controlled digital routes
HCP, patient and public-facing routes were clearly signposted
Prescribing information was easy to locate and consistently handled
Adverse-event reporting or safety routes were visible
Product information appeared coherent across websites, pages, portals, listings and microsites
The estate appeared maintainable across a wider product portfolio
0-10
The individual assessments were combined into a single 0–10 maturity scale — where a higher score reflects a clearer, more coherent and better-governed estate.
What the report includes
The full benchmark report covers findings, methodology, named exemplars, a Big Pharma comparator analysis, and a practical self-assessment framework you can use internally.
Maturity scores and market positioning
How 100 UK POM MAHs scored across digital estate maturity, with aggregate and segment-level analysis
Named exemplars
Companies with stronger visible product-information estates, identified and explained
Big Pharma comparator analysis
A reference cohort of 9 Big Pharma companies scored and compared to the core sample
Methodology and scoring framework
Transparent explanation of how companies were identified, reviewed and scored
Self-assessment framework
A practical tool you can use internally to benchmark your own estate against the findings
Private estate review option
The option to request a focused, non-published review of your own product-information estate
Some of the questions the report can help you answer
How does our product-information estate compare to others in the UK POM market?
Are we relying too heavily on third-party platforms like eMC for product visibility?
Do we have clear, separate routes for HCPs and patients?
Where do the most practical improvement opportunities sit for a company like ours?
Is our product information structured well enough to be found and surfaced correctly by AI?
What does good look like for a mid-tier or specialist MAH?